Medigene to Present at the 6th Annual CAR-TCR Summit Europe in London
MARTINSRIED, Germany and MUNICH, Germany, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage...
Cancer
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2022 Revenue
Record full-year 2022 total preliminary unaudited revenue of €55.1 million ($58.0 million) represents an increase of 25.1% over full-year 2021,...
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Calif., and SUZHOU, China and SHANGHAI, China, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global...
Morphic to Present at SVB Leerink Global Healthcare Conference
WALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral...
Athenex Announces a Reverse Stock Split
BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,...
Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company...
Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
Propella Therapeutics Announces Presentation of Updated Phase 1/2a Data of PRL-02 for the Treatment of Advanced Prostate Cancer at 2023 ASCO Genitourinary (GU) Cancers Symposium
PRL-02 continues to demonstrate strong safety along with dose-dependent reductions in testosterone and PSA Recently issued U.S. patent expands PRL-02...
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and...
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy Cord blood-derived T-Cell Receptor...
Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
AUSTIN, Texas, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination
-- NCI will lead the Phase 1 study using Gritstone’s proprietary “off the shelf” vaccine technology for mutant KRAS solid...
Monopar Announces Camsirubicin Clinical Program Update – Improved Side Effect Profile Seen to Date Compared to Doxorubicin
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
G Medical Innovations announces receipt of patent from USPTO for vital signs sensors
Rehovot, Israel, Feb. 13, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical...
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
Topline trial results expected mid-March 2023NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical...
Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards
MINNEAPOLIS, Minn, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive...
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
- Q-Code assigned to CIMERLI® for Medicare claims processing effective for dates of service on and after April 1, 2023...
Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing...
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical...
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...